PALO ALTO, Calif., Sept. 19, 2016 /PRNewswire/ -- AirXpanders Inc. (ASX: AXP), a company developing a novel technology for women undergoing tissue expansion for breast reconstruction following a mastectomy, today announced that its AeroForm® Tissue Expander System will be featured in three presentations at the American Society of Plastic Surgeons (ASPS) Plastic Surgery: The Meeting 2016, September 23-25 at the Los Angeles Convention Center (booth #1523). The ASPS is the largest specialty plastic surgery organization in the world. With more than 7,000 members, the ASPS comprises 94 percent of all board-certified plastic surgeons in the United States.
Currently under review with FDA, AeroForm is a novel patient-controlled, needle-free tissue expander which helps patients achieve full tissue expansion in weeks rather than months, allowing them to rebuild their shape faster following a mastectomy.
During the meeting, three plastic surgery leaders involved with the XPAND pivotal clinical study for AeroForm will share their experiences and clinical results:
- Friday, September 23: Dr. Kamakshi Zeidler (Los Gatos, Calif.) will provide clinicians a primer on AeroForm at the Hot Topics in Plastic Surgery session.
- Friday, September 23: Dr. Khashayar Mohebali (Marin County, Calif.) will present information detailing the use of AeroForm and clinical results to plastic surgery residents at the Resident's Day Program.
- Monday, September 26: Dr. Jeffrey Ascherman (Columbia University, New York, N.Y.) will present the results of AirXpanders' XPAND U.S. pivotal trial, a prospective, multi-center, randomized, controlled study which compared AeroForm to saline tissue expansion, at a Scientific Abstracts session.
"Drs. Ascherman, Zeidler, and Mohebali have all played a critical role in advancing the clinical understanding of AeroForm, and we are delighted these leaders can share their experiences with their esteemed peers at such an important time for the company," said Scott Dodson, president and CEO of AirXpanders. "We look forward to educating the plastic surgery community on this revolutionary technology that could change the standard of care for two-stage breast reconstruction."
For more information about AeroForm, please visit AirXpanders at ASPS Plastic Surgery: The Meeting in booth #1523.
In parallel, Jessica Biddy, an Aesthetic Nurse Specialist, will present key findings from the XPAND trial to an audience of nurses on Saturday, September 24 at the American Society of Plastic Surgery Nurses (ASPSN) meeting taking place concurrently in Los Angeles, California.
Founded in 2005, AirXpanders, Inc. (www.airxpanders.com) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The company's flagship product, the AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy. Headquartered in Palo Alto, California, AirXpanders is committed to providing patients and surgeons with best-in-class products that are made under strict design and quality standards.
AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction. AirXpanders is a publically listed company on the Australian Stock Exchange under the symbol AXP. The AeroForm Tissue Expander System is not cleared or approved for use in the United States and is for investigational use only. AeroForm is cleared for commercialization in Europe and in Australia.
Michelle Thaler/Wendy Ryan
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/airxpanders-aeroform-tissue-expander-system-for-breast-reconstruction-to-be-featured-in-three-presentations-at-american-society-of-plastic-surgery-meeting-in-los-angeles-california-300330141.html
SOURCE AirXpanders Inc.